<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01611844</url>
  </required_header>
  <id_info>
    <org_study_id>2009.591</org_study_id>
    <nct_id>NCT01611844</nct_id>
  </id_info>
  <brief_title>Optimization of Tuberculosis Intradermal Skin Test</brief_title>
  <acronym>TB Dermatest</acronym>
  <official_title>Optimization of Tuberculosis Intradermal Skin Test: TB Dermatest WP 3.1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The only test available for in vivo diagnosis of tuberculosis is the intradermal injection of&#xD;
      tuberculin according to the Mantoux method (also named tuberculosis skin test or PPD skin&#xD;
      test).&#xD;
&#xD;
      The tuberculin skin test is based on a delayed-type hypersensitivity skin reaction However,&#xD;
      this test needs to be performed by trained personnel, presents problem of reproducibility,&#xD;
      and its interpretation is not well standardized (measure in millimeters of skin induration 48&#xD;
      to 72 hours after the PPD skin test).&#xD;
&#xD;
      The new generation BD micro needle used in this study should solve the technical&#xD;
      difficulties; intradermal administration of tuberculin could then be made by any personnel.&#xD;
&#xD;
      A non-invasive and objective instrumental method of reading the test will be also tested .&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>hypersensitivity reaction to tuberculin measured in millimeters of skin induration by comparing two methods of intradermal injection (Mantoux and BD micro-needle). [Phase 1]</measure>
    <time_frame>72 h</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>spectroscopy instrumentation(non-invasive and objective method)to measure the PPD reaction</measure>
    <time_frame>72 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>define changes in the cutaneous immune system at various times (7h, 24h and 48 h), induced by intradermal microinjection of tuberculin, by histological, immunohistochemical and molecular analysis</measure>
    <time_frame>48 h</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Medical device : micro-needle BD 1.5 mm 30G</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Manthoux method: lance 26G X 16mm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Medical device : micro-needle BD 1.5 mm 30G drug:Tubertest® : tuberculin (purified protein derivative)</intervention_name>
    <description>2 intradermal injections are performed on each arm/bottom of the subject:&#xD;
1 intradermal injection of Tuberculin (5UI)&#xD;
1 intradermal injection of saline solution using Manthoux method or BD micro-needle. the method of injection is randomized: left or right</description>
    <arm_group_label>Medical device : micro-needle BD 1.5 mm 30G</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>medical device: lance 26G X 16mm drug: Tubertest® : tuberculin (purified protein derivative)</intervention_name>
    <description>2 intradermal injections are performed on each arm/bottom of the subject:&#xD;
1 intradermal injection of Tuberculin (5UI)&#xD;
1 intradermal injection of saline solution using Manthoux method or BD micro-needle. the method of injection is randomized: left or right</description>
    <arm_group_label>Manthoux method: lance 26G X 16mm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject aged 18 years or over&#xD;
&#xD;
          -  Tuberculosis skin test (PPD)&#xD;
&#xD;
          -  positive : 5mm =&lt;PPD&lt;15mm (24 subjects)&#xD;
&#xD;
          -  negative: PPD &lt; 5mm (6 subjects)&#xD;
&#xD;
          -  Negative Quantiferon test.&#xD;
&#xD;
          -  Legal capacity to consent&#xD;
&#xD;
          -  Subject had given written consent before his participation&#xD;
&#xD;
          -  Subject accepting to participate in the second phase of the study with skin biopsies&#xD;
             (24 subjects with positive PPD)&#xD;
&#xD;
          -  Females of childbearing potential using an effective method of contraception, for at&#xD;
             least 1 month before the beginning of the study and until 1 month after the end of&#xD;
             their participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known allergy to tuberculin&#xD;
&#xD;
          -  History of severe skin reaction to tuberculin with vesicle, ulceration, necrosis&#xD;
&#xD;
          -  History of active tuberculosis&#xD;
&#xD;
          -  Latent tuberculosis (positive Quantiferon test)&#xD;
&#xD;
          -  Contact with a person having or having had active tuberculosis in the previous 3&#xD;
             months&#xD;
&#xD;
          -  Chronic disease non-stabilized under treatment&#xD;
&#xD;
          -  Immunosuppressive therapy or corticosteroids within 1 month before PPD skin tests&#xD;
&#xD;
          -  Non-steroid anti-inflammatory drugs within 1 week before PPD skin tests&#xD;
&#xD;
          -  Application on study areas of topical drugs containing corticoids or&#xD;
             immunosuppressants within 1 week before PPD skin test&#xD;
&#xD;
          -  Dermatological disease on study area&#xD;
&#xD;
          -  Known allergy to local anesthetics&#xD;
&#xD;
          -  Wound healing disorders&#xD;
&#xD;
          -  Subject in an exclusion period or participating or planning to participate in another&#xD;
             biomedical research&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catherine GOUJON, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Lyon Sud -Hospices Civils de Lyon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Unité de Recherche Clinique en Immunologie Lyon Sud (URCI-LS) et Service d'Immunologie clinique et allergologie-Centre Hospitalier Lyon Sud -Hospices Civils de Lyon</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <study_first_submitted>December 22, 2011</study_first_submitted>
  <study_first_submitted_qc>May 31, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2012</study_first_posted>
  <last_update_submitted>July 30, 2013</last_update_submitted>
  <last_update_submitted_qc>July 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 31, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>delayed-type hypersensitivity reaction to tuberculin intradermal injection</keyword>
  <keyword>tuberculosis skin test</keyword>
  <keyword>BD micro-needle</keyword>
  <keyword>medical device</keyword>
  <keyword>spectroscopy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

